Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

Company Overview - Johnson & Johnson (JNJ) has a diversified business model, operating through pharmaceuticals and medical devices divisions, with over 275 subsidiaries, which enhances its resilience against economic cycles [11] - The company has 26 platforms generating more than $1 billion in annual sales and maintains one of the largest R&D budgets among pharmaceutical companies [11] Investment Ratings - JNJ is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position but not a strong buy [12] - The Momentum Style Score for JNJ is B, with shares having increased by 5.4% over the past four weeks [12] Earnings Estimates - In the last 60 days, eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate rising by $0.06 to $10.60 per share [12] - JNJ has an average earnings surprise of 5.7%, suggesting a history of exceeding earnings expectations [12] Investment Consideration - With a solid Zacks Rank and strong Momentum and VGM Style Scores, JNJ is recommended for investors' consideration [13]